Yang-june Im, Ph.D.
Affiliations: | 2003 | The University of Southern Mississippi, Hattiesburg, MS, United States |
Area:
Mass Communications, Journalism, Industrial PsychologyGoogle:
"Yang-june Im"Parents
Sign in to add mentor| Mazharul Haque | grad student | 2003 | University of Southern Mississippi | |
| (A profile of news people working in the Korean daily newspapers.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lee SY, Kim EK, Kim JY, et al. (2020) The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer. Scientific Reports. 10: 18647 |
| Swain SM, Miles D, Kim SB, et al. (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet. Oncology |
| Sim SH, Park IH, Jung KH, et al. (2019) Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). British Journal of Cancer |
| Kim EK, Cho J, Kim JY, et al. (2018) Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data. Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| Park YH, Im SA, Kim SB, et al. (2017) Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. European Journal of Cancer (Oxford, England : 1990). 86: 385-393 |
| Choi M, Park YH, Ahn JS, et al. (2016) Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. Journal of Pathology and Translational Medicine |
| Park KH, Lee S, Park JH, et al. (2016) A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer |
| Park YH, Kim TY, Im YH, et al. (2016) Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Research and Treatment : Official Journal of Korean Cancer Association |
| Harbeck N, Huang CS, Hurvitz S, et al. (2016) Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. The Lancet. Oncology |
| Park K, Choi MK, Jung HH, et al. (2015) Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget |